Article Details
Retrieved on: 2025-02-20 11:56:48
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Our lead asset, CIT-013, is a first-in-class monoclonal antibody with a unique dual mechanism of action: it enhances the clearance of existing ...
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here